Polygenic Risk Scores and Cancer Prevention
Introduction
Cancer remains one of the leading causes of morbidity and mortality worldwide. While environmental exposures such as tobacco use, diet, and occupational hazards contribute substantially to cancer risk, inherited genetic variation also plays an important role in determining individual susceptibility. Traditionally, cancer genetics has focused on rare high-penetrance mutations, such as those found in BRCA1/BRCA2 for hereditary breast and ovarian cancer or Lynch syndrome genes for colorectal cancer. Although these mutations confer significant risk, they account for only a small proportion of cancer cases.
Most cancers arise from the combined influence of numerous genetic variants, each contributing a modest increase in risk. Advances in human genomics have enabled researchers to identify these variants and integrate them into quantitative measures known as polygenic risk scores (PRS). Polygenic risk scores estimate an individual's inherited susceptibility to disease by aggregating the effects of multiple genetic variants across the genome.
In recent years, PRS have attracted increasing interest as tools for risk stratification and cancer prevention. By identifying individuals with elevated genetic risk, healthcare systems may be able to tailor screening programs, initiate earlier preventive interventions, and allocate resources more efficiently. These strategies align with the broader goals of precision medicine, which seeks to tailor healthcare strategies based on biological, environmental, and lifestyle factors.
However, despite promising research findings, the integration of PRS into routine clinical practice remains an evolving process. Questions related to clinical validity, population diversity, ethical considerations, and healthcare infrastructure must be addressed before these tools can be widely implemented.
What Polygenic Risk Scores Are
Polygenic risk scores quantify the cumulative effect of many genetic variants that contribute to disease risk. Unlike single-gene mutations that cause Mendelian disorders, polygenic traits arise from the combined influence of numerous genetic loci distributed throughout the genome.
Most variants included in PRS are single nucleotide polymorphisms (SNPs) - small changes in a single nucleotide base within the DNA sequence. Individually, these variants typically have small effects on disease risk. However, when aggregated across hundreds or thousands of loci, their combined influence can meaningfully alter an individual's overall susceptibility.
For example, genome-wide association studies have identified numerous SNPs associated with breast cancer, prostate cancer, colorectal cancer, and lung cancer. By combining the effects of these variants into a single score, researchers can estimate an individual's inherited cancer risk relative to the general population.
Polygenic risk scores therefore provide a probabilistic measure of susceptibility rather than a deterministic prediction. Individuals with high PRS may have significantly elevated risk compared with population averages, but environmental exposures and lifestyle behaviors remain important determinants of disease outcomes.
How Polygenic Risk Scores Are Calculated
Genome-Wide Association Studies
The development of polygenic risk scores relies heavily on data generated from genome-wide association studies (GWAS). GWAS analyze genetic variation across large populations to identify variants associated with specific diseases.
In a typical GWAS, researchers compare the genomes of individuals with a disease to those without the condition. By examining millions of genetic variants across the genome, they identify loci that occur more frequently in affected individuals. These loci are then statistically associated with disease risk.
Over the past two decades, GWAS have identified thousands of risk-associated variants for various cancers. Many of these variants lie within noncoding regions of the genome and may influence gene regulation rather than directly altering protein structure.
Although each individual variant contributes only a small increase in risk, their cumulative effects can be substantial. These discoveries have provided the foundation for constructing polygenic risk scores.
Risk Modeling
Polygenic risk scores are calculated by summing the contributions of multiple genetic variants, each weighted according to its estimated effect size derived from GWAS data. The resulting score represents an individual's genetic susceptibility relative to population averages.
Mathematically, the PRS can be expressed as the sum of risk alleles carried by an individual, each multiplied by its corresponding effect size. Advanced statistical models may incorporate thousands of variants simultaneously.
The predictive performance of a polygenic risk score depends on several factors, including:
The number of variants included in the model
The accuracy of effect size estimates
The size and diversity of the populations used to derive the model
Large biobank datasets, such as the UK Biobank and other international genomic initiatives, have significantly improved the development and validation of PRS models.
Clinical Applications in Cancer Prevention
Breast Cancer Screening
Breast cancer represents one of the most extensively studied areas for polygenic risk scoring. Traditional screening guidelines are largely based on age and family history. However, these criteria do not fully capture the heterogeneity of breast cancer risk across individuals.
Polygenic risk scores may help refine breast cancer screening strategies by identifying women who are at higher or lower genetic risk. Studies have shown that PRS can stratify women into risk categories that differ substantially from population averages.
For example, women in the highest percentile of polygenic risk may have several-fold higher lifetime risk of breast cancer compared with those at average risk. In contrast, individuals with very low PRS may have substantially reduced risk.
These insights could potentially inform risk-adapted screening strategies, such as initiating screening at earlier ages for high-risk individuals or adjusting screening intervals based on genetic risk. Several research initiatives are currently evaluating whether integrating PRS into breast cancer screening programs can improve early detection while reducing unnecessary screening.
Lung Cancer Risk Prediction
Lung cancer remains the leading cause of cancer-related mortality worldwide. Current screening recommendations primarily focus on individuals with significant smoking histories. However, not all smokers develop lung cancer, and some individuals with limited smoking exposure may still develop the disease.
Recent research suggests that polygenic risk scores based on germline genetic variants may improve lung cancer risk prediction when combined with traditional risk factors such as smoking history. Studies have demonstrated that PRS can identify individuals with elevated genetic susceptibility who may benefit from earlier or more intensive screening strategies.
For example, individuals with both high genetic risk and substantial smoking exposure may represent a particularly high-risk group. Integrating genetic risk scores into existing risk prediction models could therefore improve the targeting of lung cancer screening programs.
Challenges in Implementing Polygenic Risk Scores
Population Bias
One of the most significant challenges in the development of polygenic risk scores is population bias. Many genomic studies have historically focused on populations of European ancestry, leading to risk models that may not perform equally well in other populations.
Genetic variation differs across populations due to historical migration patterns, demographic events, and natural selection. As a result, PRS models developed in one population may produce less accurate risk estimates when applied to individuals from different ancestral backgrounds.
Addressing this limitation requires expanding genomic research to include diverse populations and developing risk models that are validated across multiple ethnic and geographic groups.
Clinical Implementation
Translating polygenic risk scores from research settings into clinical practice presents additional challenges. Healthcare systems must consider several factors when evaluating the potential use of PRS:
Clinical utility: Evidence must demonstrate that PRS improves patient outcomes or prevention strategies.
Integration with existing risk models: Genetic risk scores must be combined with clinical and environmental risk factors.
Healthcare infrastructure: Genetic testing and interpretation require specialized expertise and resources.
Ethical considerations: Ensuring equitable access to genomic testing and protecting patient privacy are essential priorities.
Furthermore, communicating genetic risk information to patients requires careful consideration. Risk estimates must be presented in ways that are understandable and actionable while avoiding unnecessary anxiety or misunderstanding.
Future Research Directions
The field of polygenic risk prediction continues to evolve rapidly. Several developments may shape the future integration of PRS into cancer prevention strategies.
First, increasing availability of large-scale genomic datasets will likely improve the accuracy of risk prediction models. International collaborations and biobank initiatives are expanding the diversity and scale of genomic research populations.
Second, researchers are exploring multi-factor risk models that integrate genetic, environmental, and lifestyle data. Combining polygenic risk scores with behavioral and environmental risk factors may produce more accurate predictions of disease susceptibility.
Third, advances in computational methods and artificial intelligence may enable more sophisticated modeling of complex genetic interactions.
Finally, prospective clinical trials will be necessary to evaluate whether PRS-guided screening programs improve clinical outcomes. Such studies will provide essential evidence for policymakers and healthcare systems considering the implementation of genomic risk assessment tools.
Conclusion
Polygenic risk scores represent an emerging tool in precision medicine that has the potential to improve cancer prevention strategies. By aggregating the effects of multiple genetic variants, PRS provide a quantitative measure of inherited susceptibility to disease.
Applications in breast cancer screening and lung cancer risk prediction illustrate how genetic risk information may complement traditional risk factors. However, several challenges including population bias, clinical implementation, and ethical considerations must be addressed before PRS can be widely integrated into routine healthcare.
Continued research, expanded genomic diversity in studies, and careful clinical validation will be essential for translating polygenic risk prediction into effective cancer prevention strategies. For clinicians and healthcare leaders, understanding the capabilities and limitations of PRS will be increasingly important as genomic technologies continue to influence the future of precision medicine.
References
Khera AV, et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nature Medicine.
Chatterjee N, et al. Developing and evaluating polygenic risk prediction models for stratified disease prevention. Nature Reviews Genetics.
Mavaddat N, et al. Polygenic risk scores for prediction of breast cancer risk. Nature Genetics.
Hung RJ, et al. Incorporating genetic susceptibility into lung cancer risk prediction models. Nature Communications.
Lewis ACF, Green RC. Polygenic risk scores in the clinic: new perspectives needed on familiar ethical issues. Genome Medicine.
